ResMed Inc. (NYSE:RMD - Get Free Report) General Counsel Michael J. Rider sold 64 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $222.86, for a total value of $14,263.04. Following the transaction, the general counsel now owns 8,846 shares of the company's stock, valued at approximately $1,971,419.56. This represents a 0.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
ResMed Stock Down 4.4 %
Shares of NYSE:RMD opened at $213.11 on Friday. ResMed Inc. has a 1 year low of $172.19 and a 1 year high of $263.05. The firm has a market capitalization of $31.30 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74. The business has a 50 day simple moving average of $231.65 and a two-hundred day simple moving average of $237.37. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, equities analysts predict that ResMed Inc. will post 9.47 EPS for the current year.
ResMed Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date was Thursday, February 13th. ResMed's dividend payout ratio (DPR) is presently 25.03%.
Wall Street Analysts Forecast Growth
RMD has been the subject of several research reports. JPMorgan Chase & Co. upped their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Stifel Nicolaus lowered their price objective on ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a research report on Wednesday, March 5th. Morgan Stanley started coverage on shares of ResMed in a research report on Wednesday, March 19th. They issued an "overweight" rating and a $280.00 target price on the stock. Citigroup raised shares of ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Finally, KeyCorp upped their price target on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, ResMed currently has an average rating of "Moderate Buy" and a consensus price target of $249.73.
Get Our Latest Analysis on RMD
Institutional Trading of ResMed
Several institutional investors and hedge funds have recently bought and sold shares of the business. Colonial Trust Co SC grew its position in ResMed by 6,250.0% during the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 125 shares during the period. Optiver Holding B.V. acquired a new position in shares of ResMed during the 4th quarter worth about $33,000. Itau Unibanco Holding S.A. raised its holdings in shares of ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 150 shares during the last quarter. OFI Invest Asset Management acquired a new stake in ResMed during the 4th quarter worth $39,000. Finally, Coppell Advisory Solutions LLC boosted its position in ResMed by 1,750.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 185 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 175 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.
About ResMed
(
Get Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
